Zvonko Milicevic Selected Research

Therapeutics

1/2022	LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
11/2018	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
1/2018	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
9/2009	Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial.
11/2007	Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
1/2002	Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zvonko Milicevic Research Topics

Disease

30	Type 2 Diabetes Mellitus (MODY) 12/2023 - 01/2002
8	Body Weight (Weight, Body) 08/2023 - 01/2002
6	Vomiting 12/2023 - 08/2014
6	Nausea 12/2023 - 08/2014
6	Weight Loss (Weight Reduction) 08/2023 - 11/2018
6	Hyperglycemia 03/2009 - 01/2002
3	Obesity 08/2023 - 01/2022
2	Insulin Resistance 01/2022 - 01/2021
2	Latent Autoimmune Diabetes in Adults 01/2018 - 01/2018
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2018 - 09/2009
2	Stroke (Strokes) 01/2016 - 07/2011
2	Myocardial Infarction 07/2011 - 03/2009
2	Cough 09/2009 - 09/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2005 - 02/2003
2	Hypoglycemia (Reactive Hypoglycemia) 12/2003 - 01/2002
1	Constipation 12/2023
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 11/2022
1	Weight Gain 11/2017
1	Abdominal Pain (Pain, Abdominal) 01/2017
1	Pancreatitis 01/2017
1	Cardiogenic Shock 05/2015
1	Ventricular Fibrillation 05/2015
1	Pneumonia (Pneumonitis) 05/2015
1	Diarrhea 08/2014
1	Acute Coronary Syndrome 07/2011
1	Dyspnea (Shortness of Breath) 09/2009
1	Glucose Intolerance 02/2008
1	Diabetes Mellitus 11/2007
1	Infarction (Infarctions) 03/2005
1	Inflammation (Inflammations) 11/2003
1	Genetic Predisposition to Disease (Genetic Predisposition) 11/2003

Drug/Important Bio-Agent (IBA)

17	dulaglutideIBA 12/2023 - 08/2014
12	Insulin (Novolin)FDA Link 11/2017 - 03/2002
11	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 08/2014
11	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 12/2003
9	Insulin Lispro (Humalog)FDA Link 10/2016 - 01/2002
8	Glucose (Dextrose)FDA LinkGeneric 11/2022 - 02/2008
8	Blood Glucose (Blood Sugar)IBA 01/2022 - 02/2003
8	Insulin Glargine (Lantus)FDA Link 11/2019 - 03/2005
6	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2023 - 10/2012
6	tirzepatideIBA 11/2023 - 11/2018
4	retatrutideIBA 12/2023 - 01/2022
4	Peptides (Polypeptides)IBA 11/2022 - 11/2018
4	Hemoglobins (Hemoglobin)IBA 11/2017 - 12/2003
3	Glucagon (Glukagon)FDA Link 11/2022 - 01/2022
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2017 - 08/2014
2	Glucagon Receptors (Glucagon Receptor)IBA 12/2023 - 11/2022
2	semaglutideIBA 01/2023 - 01/2022
2	Exenatide (Byetta)FDA Link 01/2017 - 10/2012
2	Glyburide (Glibenclamide)FDA LinkGeneric 12/2003 - 01/2002
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2023
1	LipidsIBA 11/2023
1	Hormones (Hormone)IBA 08/2023
1	Insulin-Like Growth Factor Binding Protein 1IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Insulin-Like Growth Factor Binding Protein 2IBA 01/2021
1	AdiponectinIBA 01/2021
1	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2020
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2018
1	SodiumIBA 01/2018
1	AntibodiesIBA 01/2018
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2018
1	EnzymesIBA 01/2017
1	Liraglutide FDA Link 10/2012
1	Carbon MonoxideIBA 09/2009
1	InsulinsIBA 11/2007
1	isophane insulin lispro drug combination (25:75) insulin lisproIBA 12/2005
1	Isophane Insulin (NPH Insulin)FDA Link 03/2005
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2003
1	Fibrinogen (Factor I)FDA Link 11/2003
1	Human Regular Insulin (Humulin)IBA 03/2002

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2002
6	Glycemic Control 01/2022 - 01/2002
4	Injections 09/2009 - 12/2005
1	Subcutaneous Injections 01/2018